Likewise, the decreased seropositivity rate in patients on anti-TNF therapy confirms previous studies that reported reduced humoral immune responses after SARS-CoV-2 infection in IBD patients on anti-TNF agents [5, 19]. Here, TNF is linked to inflammatory bowel disease.